Revolo Biotherapeutics to Present at the 8th Food Allergy Fund Summit

NEW ORLEANS and CAMBRIDGE, England, April 13, 2023 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that management will be presenting at the 8^th Food Allergy Fund Summit being held on April 20, 2023, at the Paley Center for Media in New York City.

The summit will showcase the most relevant and cutting-edge developments in food allergy research and innovation in 2023. Revolo’s Group CEO, Jonathan Rigby, will provide an overview of the company’s lead candidate, ‘1104, its immune-resetting asset that has recently completed two Phase 2a clinical trials for the treatment of eosinophilic esophagitis (EoE) and allergic disease, with anticipated data readouts in Q2 2023 and mid 2023 respectively. Mr. Rigby will also discuss ‘1104’s potential to be an allergen-agnostic therapeutic for the treatment of multiple allergic diseases, including food allergy.

Presentation details
Session: Key innovations: Microbiome therapy
Time: 9:30 am ET
Presenter: Jonathan Rigby, Group CEO of Revolo

Revolo Biotherapeutics
Revolo Biotherapeutics is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic disease, without the immune system suppression seen with current therapies. Its two drug candidates, ‘1805 and ‘1104, a protein and a peptide respectively, reset the immune system to prevent the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. ‘1805 is a modified analogue of a key protein in immune function nearing initiation of a second Phase 2b clinical trial for moderate-to-severe rheumatoid arthritis and a Phase 2a clinical trial for an additional autoimmune indication. ‘1104 is a peptide derived from a natural immune-regulatory protein and has recently completed a Phase 2a clinical trial for patients with eosinophilic esophagitis (EoE) with data expected in Q2 2023. ‘1104 is also being evaluated in a recently completed Phase 2a clinical trial for allergic disease with data expected mid 2023. The disease-agnostic mechanism of action of Revolo Biotherapeutic’s assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.

For further information, please visit www.revolobio.com.

Company Contact
Marylyn Rigby, VP Investor Relations & Marketing
mrigby@revolobio.com

Media Contact
Monica Rouco Molina, Ph.D.
LifeSci Communications
+1-929-469-3850
mroucomolina@lifescicomms.com